Literature DB >> 1898951

Reasons for the lack of benefit of immediate angioplasty during recombinant tissue plasminogen activator therapy for acute myocardial infarction: a regional wall motion analysis. European Cooperative Study Group.

A E Arnold1, P W Serruys, W Rutsch, M L Simoons, D P de Bono, J G Tijssen, J Lubsen, M Verstraete.   

Abstract

Regional ventricular wall motion analysis utilizing three different methods was performed on predischarge left ventriculograms from 291 of 367 patients enrolled in a randomized trial of single chain recombinant tissue-type plasminogen activator (rt-PA), aspirin and heparin with and without immediate angioplasty in patients with acute myocardial infarction. With univariate analysis, no difference in regional wall motion variables between the two treatment groups was observed. However, with individual baseline risk assessment by multivariate linear regression analysis using baseline characteristics known to be related to left ventricular function after thrombolytic therapy or outcome of coronary angioplasty, or both, an excess of high risk patients in the invasive treatment group was detected. To adjust for this unequal distribution of baseline risk, multivariate linear regression analysis was performed. No benefit of immediate coronary angioplasty was observed after adjustment. Reocclusion or reinfarction, or both, occurred more frequently in the invasive than in the noninvasive treatment group (18% versus 13%, respectively). Among patients with a patent infarct-related vessel on angiography between days 10 and 22 and without reinfarction before angiography, there was a trend toward benefit from the invasive strategy, indicating that reocclusion and reinfarction might be responsible for the lack of benefit of the invasive strategy. This implies that immediate coronary angioplasty may be beneficial in selected patients, provided that these complications can be prevented.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898951     DOI: 10.1016/0735-1097(91)90699-a

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

Review 1.  Treating myocardial infarction in the post-GUSTO era. A European perspective.

Authors:  M J de Boer; F Zijlstra
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

Review 2.  Immediate angioplasty after thrombolysis: a systematic review.

Authors:  Warren J Cantor; Fabrice Brunet; Carolyn P Ziegler; Alex Kiss; Laurie J Morrison
Journal:  CMAJ       Date:  2005-12-06       Impact factor: 8.262

Review 3.  Recent advances in cardiology.

Authors:  C F Shakespeare; D J Coltart
Journal:  Postgrad Med J       Date:  1992-05       Impact factor: 2.401

Review 4.  Systematic review of fibrinolytic-facilitated percutaneous coronary intervention: potential benefits and future challenges.

Authors:  J Afilalo; A Michael Roy; M J Eisenberg
Journal:  Can J Cardiol       Date:  2009-03       Impact factor: 5.223

Review 5.  Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.

Authors:  J C Gillis; A J Wagstaff; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

6.  Early vs Late Coronary Angiography and Intervention Following Thrombolytic Therapy; a Cohort Study.

Authors:  Bahareh Feizi; Shahram Taghdisi; Jalil Etemadi; Amir Hossein Feizi; Setareh Asgarzadeh; Sepideh Kamal
Journal:  Emerg (Tehran)       Date:  2017-01-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.